沙格列汀一水合物  98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
包装规格:5mg 10mg 50mg 100mg in glass bottle
产品简介:一种有效,选择性,可逆,竞争性和具有口服活性的二肽基肽酶 4 (DPP-4) (Ki = 0.6-1.3 nM) 抑制剂。Saxagliptin hydrate 可用于 2 型糖尿病的研究。
体内实验:DMSO :66 mg/mL (197.94 mM) Ethanol:66 mg/mL (197.94 mM) Water:1 mg/mL (2.99 mM)
靶点:DPP-4
体外研究:Saxagliptin (100 nM; 48 hours; INS-1 832/13 cells) treatment significantly induceS β-cell proliferation. Saxagliptin (100 nM; 48 hours; INS-1 832/13 cells) treatment increases the p-AKT and active β-catenin protein levels, paralleled with the increase of c-myc and cyclin D1 protein expression. Saxagliptin acts by preventing the degradation of glucagon-like peptide-1 and hence increases secretion of insulin and decreases secretion of glucagon.
体内研究:Saxagliptin (1 mg/kg; for 12 weeks) treatment in high-fat diet/streptozotocin-induced diabetic rats, significant improvement in pancreas insulin secretion capacity evaluated by hyperglycemia clamp and increased β-cell to α-cell areas ratio are observed. Saxagliptin dose-dependently inhibits plasma DPP-4 activity in Han-Wistar rats, by ~70% at 7 hours postdose with 1 mg/kg and by ~90% at 7 hours postdose with 10 mg/kg. At 24 hours postdose, ~20% and 70% inhibition, respectively, remained.
细胞实验:细胞系:骨髓基质细胞(MSC); MC3T3E1成骨样细胞 浓度:1.5 或 15 μM 处理时间:24 h 或 1 h 方法:亚融合状态的细胞先进行过夜血清饥饿,然后用1.5或15 μM saxagliptin和/或FBS (1%), insulin (5 ng/mL)或IGF1 (10-8 M)孵育24小时(用于检测细胞增殖)或1小时(用于检测信号转导机制)。
动物实验:动物模型:C57BLKS/J成年小鼠;db/db小鼠 剂量:0.1 mg/kg 给药处理:口服
保存条件:-20°C
注意事项:1、为了您的安全和健康,请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。